Safety checklist

At-home ketamine safety checklist

At-home ketamine can mean prescribed compounded oral or sublingual ketamine through telehealth where allowed; it does not mean take-home Spravato, psilocybin, MDMA, LSD, ayahuasca, ibogaine, or 5-MeO-DMT. Use this checklist before any program ships medication.

If you are in immediate danger or thinking about harming yourself, do not use this page as your first step. Call emergency services, call or text 988 in the United States, or use our crisis resources. At-home ketamine is not emergency care.

What is actually available at home?

Option At home? What it means Main caution
Compounded oral/sublingual ketamine Sometimes Telehealth or hybrid prescription of compounded lozenges, troches, or rapid-dissolve tablets. Not FDA-approved for psychiatric disorders; no onsite monitoring during acute effects.
Spravato (esketamine) No FDA-approved nasal spray for treatment-resistant depression and certain acute suicidal ideation indications. Must be administered in a certified healthcare setting under REMS with at least two hours of monitoring.
Remote integration therapy Yes Preparation or post-session therapy by video with a licensed clinician or trained integration provider. Useful support, but it is not legal remote dosing for Schedule I psychedelics.
Psilocybin, MDMA, LSD, ayahuasca, ibogaine, 5-MeO-DMT No legal take-home treatment These remain Schedule I federally in the US, except specific religious/state-regulated contexts that are not take-home medical treatment. At-home sourcing or self-administration creates legal and safety risk.

Do not start with at-home dosing if any of these apply

  1. Current crisis or unstable self-harm risk. At-home treatment is not a substitute for emergency or urgent psychiatric care.
  2. Active psychosis, mania, or bipolar I instability. Ketamine can worsen psychiatric symptoms in vulnerable patients.
  3. Uncontrolled hypertension, major cardiac disease, or recent cardiovascular event. Ketamine can raise blood pressure and heart rate.
  4. Substance-use disorder or ketamine misuse risk. Ketamine has abuse and diversion risk; large take-home quantities are a red flag.
  5. Pregnancy, seizure instability, or complex medical status. These need clinician review before any dosing model.
  6. No sober support person or no safe setting. Dissociation, sedation, panic, or impaired coordination can happen during the session.
  7. No follow-up plan. If the program cannot tell you who checks on you after dosing, pause.

Questions for an at-home ketamine program

  • Is the evaluation live video, phone-only, or just a form?
  • Who prescribes, and are they licensed in my state?
  • How do you check blood pressure and cardiac risk?
  • Do you require a sober support person during dosing?
  • How many doses ship at once, and how are refills controlled?
  • What symptoms mean I should stop and seek urgent care?
  • Do you coordinate with my psychiatrist or therapist?

Home setup before a dose

  • No driving, childcare, cooking, or machinery for the session window.
  • Use a calm room with a place to lie down and a clear path to the bathroom.
  • Have a sober support person reachable or present, based on the clinician's instructions.
  • Keep emergency contacts, medication list, allergies, and clinic phone number visible.
  • Store medication securely away from children, guests, and anyone else in the home.
  • Do not increase dose or frequency outside the prescribing plan.

Red flags

  • No clinician evaluation before shipment.
  • No blood-pressure or medical-history review.
  • Claims that compounded ketamine is FDA-approved for depression.
  • Unlimited refills or dose escalation without reassessment.
  • No plan for panic, vomiting, respiratory symptoms, or severe dissociation.
  • Marketing that frames ketamine as a guaranteed cure.

When in-clinic care is a better fit

  • You need insurance coverage, especially for Spravato.
  • You have blood-pressure, cardiac, or medication complexity.
  • You are worried about misuse or taking more than prescribed.
  • You live alone and cannot arrange support.
  • You want the most monitored version of ketamine care.

Official sources to know

FDA compounded ketamine warning

FDA warns that compounded ketamine products, including oral forms, are not FDA-approved for psychiatric disorders and that at-home use lacks onsite monitoring.

Read FDA warning (opens in new tab)

DEA telemedicine flexibilities

DEA and HHS extended controlled-substance telemedicine flexibilities through December 31, 2026, subject to DEA guidance, federal rules, and state law.

Read DEA update (opens in new tab)

Crisis support

If you are seeking at-home treatment because symptoms feel urgent or unsafe, use crisis support before provider shopping.

Crisis resources

Frequently asked

What psychedelic-adjacent treatment is actually available at home?

In the United States, the main legal at-home option is compounded oral or sublingual ketamine prescribed by a licensed clinician, usually through telehealth, where allowed by federal and state law. Remote integration therapy can also happen at home, but it is not dosing. Spravato, psilocybin, MDMA, LSD, ayahuasca, ibogaine, and 5-MeO-DMT are not legal take-home treatment options.

Can Spravato be taken at home?

No. Spravato is available only through the Spravato REMS and must be administered under direct observation in a certified healthcare setting with monitoring for at least two hours. It must never be dispensed directly to a patient for home use.

Is at-home compounded ketamine FDA-approved for depression?

No. FDA-approved ketamine is an injectable anesthetic, and Spravato is FDA-approved esketamine for certain depression indications under REMS. Compounded oral, sublingual, or nasal ketamine products are not FDA-approved for psychiatric disorders, and FDA has warned about risks when they are used at home without onsite monitoring.

How long does a ketamine troche last?

A ketamine troche (sublingual lozenge) typically produces effects beginning within 10–20 minutes of dissolving under the tongue. The acute dissociative and mood-altering effects last approximately 45–75 minutes at standard therapeutic doses (100–300 mg). Residual sedation and mild disorientation can persist for 1–2 hours after the troche dissolves. Driving, operating machinery, or complex tasks should be avoided for at least 4 hours after dosing. Duration varies by dose, individual metabolism, and whether the lozenge is held sublingually (faster onset) or swallowed (slower onset, reduced effect).

Who should not start with at-home ketamine?

At-home ketamine is a poor starting point for anyone in suicidal crisis, anyone with active psychosis or mania, uncontrolled blood pressure or major cardiac risk, pregnancy, significant substance-use risk, no sober support person, no safe setting, or no reliable follow-up with a clinician.

Next steps

Find a ketamine therapy provider

provider directory with at-home, clinic, and Spravato filters

Depression treatment path

compare at-home, in-clinic, Spravato, and psilocybin

Ketamine therapy guide

evidence, safety, and access models

Find an integration therapist

support before and after dosing

Crisis resources

if symptoms feel urgent or unsafe
Educational only, not medical advice. At-home ketamine usually means compounded oral or sublingual ketamine prescribed by a licensed clinician where telehealth prescribing is allowed. Compounded ketamine products are not FDA-approved for psychiatric disorders, and home use lacks onsite monitoring for sedation, dissociation, blood pressure changes, respiratory depression, misuse, and psychiatric events.
Last reviewed: 2026-05-02. Tell us what's changed — corrections@mindmedicinelaw.com.

Get the daily briefing in your inbox

Law, clinical science, and policy signal on psychedelic research — on our publish cadence. Start at the The Psychedelic Journal homepage.

Subscribe free